首页> 美国卫生研究院文献>Cancer Science >Impairment of K‐Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR‐143
【2h】

Impairment of K‐Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR‐143

机译:新型合成miR-143损害K-Ras信号网络并提高表皮生长因子受体抑制剂的功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite considerable research on K‐Ras inhibitors, none had been established until now. We synthesized nuclease‐resistant synthetic miR‐143 (miR‐143#12), which strongly silenced K‐Ras, its effector signal molecules AKT and ERK, and the K‐Ras activator Sos1. We examined the anti‐proliferative effect of miR‐143#12 and the mechanism in human colon cancer DLD‐1 cell (G13D) and other cell types harboring K‐Ras mutations. Cell growth was markedly suppressed in a concentration‐dependent manner by miR‐143#12 (IC50: 1.32 nmol L−1) with a decrease in the K‐Ras mRNA level. Interestingly, this mRNA level was also downregulated by either a PI3K/AKT or MEK inhibitor, which indicates a positive circuit of K‐Ras mRNA expression. MiR‐143#12 silenced cytoplasmic K‐Ras mRNA expression and impaired the positive circuit by directly targeting AKT and ERK mRNA. Combination treatment with miR‐143#12 and a low‐dose EGFR inhibitor induced a synergistic inhibition of growth with a marked inactivation of both PI3K/AKT and MAPK/ERK signaling pathways. However, silencing K‐Ras by siR‐KRas instead of miR‐143#12 did not induce this synergism through the combined treatment with the EGFR inhibitor. Thus, miR‐143#12 perturbed the K‐Ras expression system and K‐Ras activation by silencing Sos1 and, resultantly, restored the efficacy of the EGFR inhibitors. The in vivo results also supported those of the in vitro experiments. The extremely potent miR‐143#12 enabled us to understand K‐Ras signaling networks and shut them down by combination treatment with this miRNA and EGFR inhibitor in K‐Ras‐driven colon cancer cell lines.
机译:尽管对K-Ras抑制剂进行了大量研究,但迄今为止尚未建立。我们合成了耐核酸酶的合成miR-143(miR-143#12),它使K-Ras,其效应子信号分子AKT和ERK以及K-Ras激活剂Sos1强烈沉默。我们检查了miR-143#12的抗增殖作用及其在人结肠癌DLD-1细胞(G13D)和其他带有K-Ras突变的细胞类型中的作用机理。 miR-143#12(IC50:1.32 nmol L -1 )以浓度依赖的方式显着抑制细胞生长,同时K-Ras mRNA水平降低。有趣的是,PI3K / AKT或MEK抑制剂也下调了该mRNA水平,这表明K-Ras mRNA表达呈阳性。 MiR-143#12通过直接靶向AKT和ERK mRNA沉默了细胞质K-Ras mRNA表达,并损害了阳性电路。 miR-143#12和低剂量EGFR抑制剂的组合治疗可协同抑制生长,同时PI3K / AKT和MAPK / ERK信号通路均明显失活。但是,通过与EGFR抑制剂联合治疗,用siR-KRas代替miR-143#12沉默K-Ras不会诱导这种协同作用。因此,miR-143#12通过使Sos1沉默来扰乱K-Ras表达系统和K-Ras激活,从而恢复了EGFR抑制剂的功效。体内结果也支持体外实验的结果。极其强大的miR-143#12使我们能够了解K-Ras信号网络,并通过在K-Ras驱动的结肠癌细胞系中用这种miRNA和EGFR抑制剂联合治疗来关闭它们。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号